磷酸化蛋白质组学在肝细胞癌分子分型中的应用与研究进展

肝脏 ›› 2026, Vol. 31 ›› Issue (4): 469-473.

磷酸化蛋白质组学在肝细胞癌分子分型中的应用与研究进展

梁欣, 李超, 吴寒, 王明达, 杜祖超, 杨田

200438 上海海军军医大学第三附属医院(上海东方肝胆外科医院)肝脏外科(梁欣,李超,吴寒,王明达,杜祖超,杨田);
300070 天津天津医科大学公共卫生学院(梁欣,杨田)

收稿日期:2026-03-28 出版日期:2026-04-30 发布日期:2026-06-04
通讯作者: 杨田,Email:yangtian6666@hotmail.com
作者简介:共同第一作者:李超
基金资助:
国家自然科学基金项目(82425049,82273074);国家科技重大专项(2024ZD0520500,2024ZD0520506);上海市自然科学基金项目(22ZR1477900)

Received:2026-03-28 Online:2026-04-30 Published:2026-06-04

摘要/Abstract

摘要： 肝细胞癌(HCC)是全球发病率及死亡率位居前列的恶性肿瘤,其分子层面的高度异质性严重制约了精准诊疗的发展。随着组学技术的不断革新,HCC分子分型已从早期基于转录组的经典分型逐步演进至基因组、蛋白质组与磷酸化蛋白质组等多组学整合的新阶段。磷酸化蛋白质组学能够直接反映激酶信号通路活性状态,现已成为突破HCC精准诊疗瓶颈的重要技术路线。基于磷酸化蛋白质组学的HCC分子分型有望为患者提供个体化诊疗策略,从而有效改善临床预后。

关键词: 肝细胞癌, 分子分型, 磷酸化蛋白质组学, 精准诊疗

梁欣, 李超, 吴寒, 王明达, 杜祖超, 杨田. 磷酸化蛋白质组学在肝细胞癌分子分型中的应用与研究进展[J]. 肝脏, 2026, 31(4): 469-473.

/ 推荐

参考文献

[1] Llovet J M, Pinyol R, Kelley R K, et al.Molecular pathogenesis and systemic therapies for hepatocellular carcinoma[J]. Nat Cancer, 2022, 3(4):386-401.
[2] Wang M D, Diao Y K, Yao L Q, et al. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma[J]. ILIVER, 2024, 3(1):100083.
[3] Wang M, Wu M, Yang T. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma[J]. EBioMedicine, 2019, 40:11-12.
[4] Xing X, Hu E, Ouyang J, et al.Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy[J]. Cell Rep Med, 2023, 4(12):101315.
[5] Golkowski M, Lau H T, Chan M, et al.Pharmacoproteomics identifies kinase pathways that drive the epithelial-mesenchymal transition and drug resistance in hepatocellular carcinoma[J].Cell Syst, 2020, 11(2):196-207.e7.
[6] Bruix J,Chan S L,Galle P R, et al.Systemic treatment of hepatocellular carcinoma: an EASL position paper[J].J Hepatol, 2021, 75(4):960-974.
[7] Roskoski R Jr.Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update[J].Pharmacol Res, 2024, 200:107059.
[8] Hoshida Y, Nijman S M, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(18):7385-7392.
[9] Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, Cancer Genome Atlas Research Network.Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J].Cell, 2017, 169(7):1327-1341.e23.
[10] Rebouissou S, Nault J C.Advances in molecular classification and precision oncology in hepatocellular carcinoma[J].J Hepatol, 2020, 72(2):215-229.
[11] Gao Q, Zhu H ,Dong L, et al.Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J].Cell, 2019, 179(5):1240.
[12] Zhang Z, Zhang Z, Zhang Y, et al.Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets[J].Hepatology, 2025, 82(6):1432-1449.
[13] Ng C K Y, Dazert E,Boldanova T, et al.Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages[J].Nat Commun, 2022, 13(1):2436.
[14] Ren L, Li C, Wang Y, et al. In vivo phosphoproteome analysis reveals kinome reprogramming in hepatocellular carcinoma[J]. Mol Cell Proteomics, 2018, 17(6):1067-1083.
[15] Shoji H, Boku N, Adachi J. Clinical applications of phosphoproteomics: illuminating cancer signaling and enabling rational therapeutic strategies[J]. Cancer Sci, 2026, 117(4):885-895.
[16] Yang S, Zheng L, Li L, et al. Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma[J]. Clinical and Translational Medicine, 2024, 14(6).
[17] Muntané J, De la Rosa A J, Docobo F, et al. Targeting tyrosine kinase receptors in hepatocellular carcinoma[J]. Curr Cancer Drug Targets, 2013, 13(3):300-312.
[18] Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer[J]. Nat Med, 2014, 20(10):1138-1146.
[19] Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib[J]. Nature, 2021, 595(7869):730-734.
[20] Fan Y, Arechederra M, Richelme S, et al. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases[J]. Hepatol,2017, 66(5):1644-1661.
[21] Long H, Zhou J, Zhou C, et al.Proteomic characterization of liver cancer cells treated with clinical targeted drugs for hepatocellular carcinoma[J].Biomedicines, 2025, 13(1):152.
[22] Melas I N, Lauffenburger D A, Alexopoulos LG. Identification of signaling pathways related to drug efficacy in hepatocellular carcinoma via integration of phosphoproteomic, genomic and clinical data[J]. Proc IEEE Int Symp Bioinformatics Bioeng, 2013, 2013:14026468.
[23] Solari F A,Dell′Aica M,Sickmann A, et al.Why phosphoproteomics is still a challenge[J].Mol Biosyst,2015, 11(6):1487-1493.
[24] Ramroop J R,Stein M N,Drake J M.Impact of phosphoproteomics in the era of precision medicine for prostate cancer[J].Front Oncol, 2018, 8:28.
[25] Mantini G,Pham T V,Piersma S R, et al.Computational analysis of phosphoproteomics data in multi-omics cancer studies[J].Proteomics, 2021, 21(3-4):e1900312.
[26] Cipak L,Sivakova B,Bellova J, et al.Characterization of Ksg1 protein kinase-dependent phosphoproteome in the fission yeast S. pombe[J].Biochem Biophys Res Commun, 2024, 736:150895.